From April 1, 2024 to June 30, 2024, the company has repurchased 479,000 shares, representing 0.12% for CNY 4.01 million. With this, the company has completed the repurchase of 1,640,200 shares, representing 0.41% for CNY 19.4 million under the buyback announced on November 16, 2023.
Shanghai Labway Clinical Laboratory Co., Ltd
Equities
301060
CNE100004RG8
Healthcare Facilities & Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
7.92 CNY | +0.51% |
|
+1.54% | -40.41% |
02/07 | Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023. | CI |
30/05 | Labway Clinical Laboratory Names Chief Financial Officer | MT |
1st Jan change | Capi. | |
---|---|---|
-40.41% | 434M | |
-17.08% | 8.48B | |
+79.26% | 4.81B | |
+17.47% | 2.99B | |
-3.15% | 2.65B | |
-4.20% | 2.02B | |
-52.37% | 1.87B | |
-13.53% | 1.58B | |
+21.59% | 1.25B | |
-47.00% | 1.06B |
- Stock Market
- Equities
- 301060 Stock
- News Shanghai Labway Clinical Laboratory Co., Ltd
- Tranche Update on Shanghai Labway Clinical Laboratory Co., Ltd's Equity Buyback Plan announced on November 16, 2023.